On the contrary, opposite results were found in a small study group collected by Cefali et al. The authors concluded that KRAS mutations can be considered as a predictive marker of prolonged response to first-line ICIs in NSCLC patients with high expression of PD-L1 [66]. Here, KRAS is linked to non-small cell lung carcinoma.